The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for
antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to …

HIV-1/AIDS remains a global public health problem. The world health organization (WHO)
reported at the end of 2019 that 38 million people were living with HIV-1 worldwide, of which …

Initiating antiretroviral therapy (ART) as early as the day of HIV diagnosis is a strategy of
increasing global interest to control the HIV epidemic and optimize the health of people …

Highlights•Machine learning is increasingly used to predict and understand drug resistance
in HIV.•Phylogenetics helps to track the emergence and spread of HIV drug resistance …

Clinical studies have demonstrated that use of tenofovir disoproxil fumarate with or without
emtricitabine as antiretroviral pre-exposure prophylaxis (PrEP) can decrease the risk of …

After 15 years of global scale-up of antiretroviral therapy (ART), rising prevalence of HIV
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …

In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …

Acquired Immunodeficiency Syndrome (AIDS) is a human viral infectious disease caused by
the positive-sense single-stranded (ss) RNA Human Immunodeficiency Virus …

Background The emergence and spread of HIV-1 drug resistance may compromise HIV
control globally. In response to HIV/AIDS epidemic, China launched national HIV/AIDS …

HIV-1 has already claimed over 35 million human lives globally. No curative treatments are
currently available, and the only treatment option for over 36 million people currently living …